EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors

Taha Mansoor, Vijay Nambi, Sachin Parikh, Arunima Misra, Mahmoud Ismayl, Claire Sullivan, Laurence Sperling, Salim S Virani, Mahmoud Al Rifai, Santhosh K G Koshy, Dmitry Abramov, Abdul Mannan Khan Minhas

American Journal of Cardiovascular Drugs · 2025

DOI: 10.1007/s40256-025-00748-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Cardiovascular Drugs, 2025. Verfasst von Taha Mansoor und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, 1000 Oakland Dr, Kalamazoo, MI, 49008, USA. taha.…. Hauptthemen laut MEDLINE: Apolipoprotein C-III, Angiopoietin-Like Protein 3, Hypertriglyceridemia, Triglycerides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 81 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertriglyceridemia has been proposed as a risk factor for atherosclerotic cardiovascular disease (ASCVD). Triglycerides (TG) are viewed as a marker for remnant cholesterol in triglyceride-rich lipoproteins, as this remnant cholesterol has been identified as a causal risk factor for ASCVD. The limited number of effective treatments for elevated TG has fueled the search for novel pharmacotherapy options, and multiple medication classes are being explored. Apolipoprotein C3 (APOC3) and angiopoietin-like protein 3 (ANGPTL3) are among the most promising targets. Several novel agents utilizing these pathways, including olezarsen, plozasiran, and zodasiran, are currently under development for the management of elevated TG, with olezarsen approved in 2024 for the management of familial chylomicronemia syndrome. This comprehensive review provides updated insights into the development of novel hypertriglyceridemia treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoprotein C-IIIAngiopoietin-Like Protein 3HypertriglyceridemiaTriglyceridesHypolipidemic AgentsHumansAnimalsAtherosclerosis

Substanzen

Apolipoprotein C-IIIAngiopoietin-Like Protein 3TriglyceridesANGPTL3 protein, humanHypolipidemic AgentsAPOC3 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, 1000 Oakland Dr, Kalamazoo, MI, 49008, USA. taha.mansoor@wmed.edu.
  • Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, TX, USA.
  • Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA.
  • Department of Cardiology, Henry Ford Hospital, Detroit, MI, USA.
  • Department of Cardiology, Mayo Clinic, Rochester, MN, USA.
  • Department of Cardiology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

Zitieren

APA

Mansoor, T., Nambi, V., Parikh, S., Misra, A., Ismayl, M., Sullivan, C., Sperling, L., Virani, S. S., Rifai, M. A., Koshy, S. K. G., Abramov, D., & Minhas, A. M. K. (2025). Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-025-00748-7

Vancouver

Mansoor T, Nambi V, Parikh S, Misra A, Ismayl M, Sullivan C, et al. Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors. American Journal of Cardiovascular Drugs. 2025. doi:10.1007/s40256-025-00748-7

BibTeX
@article{Mansoor2025,
  author = {Mansoor, Taha and Nambi, Vijay and Parikh, Sachin and Misra, Arunima and Ismayl, Mahmoud and Sullivan, Claire and Sperling, Laurence and Virani, Salim S and Rifai, Mahmoud Al and Koshy, Santhosh K G and Abramov, Dmitry and Minhas, Abdul Mannan Khan},
  title = {Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors},
  journal = {American Journal of Cardiovascular Drugs},
  year = {2025},
  doi = {10.1007/s40256-025-00748-7}
}
Kostenlos starten →